David Fabrizio

Company: Foundation Medicine

Job title: Vice President, Early Clinical Development

Seminars:

Introducing an Improved Tumor Fraction to Measure ctDNA Levels, & How to Incorporate ctDNA Monitoring to Gain Early Insights & Advance Clinical Research 9:00 am

Data on the value of tumor fraction for drug development and the need to move beyond median variant allele frequency (VAF) as a measure of ctDNA Current use cases for ctDNA monitoring in early-stage disease and clinical research How different approaches to ctDNA monitoring can meet the needs for those use cases, and the benefits…Read more

day: Day One